← 產業報告目錄
CD Antigen Cancer Therapy Market Size, Share & Trends Analysis Report By Type of CD Antigen Targeted (CD19, CD20, CD30, CD33, CD38, CD70), By Therapy Type [Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy, Immunotoxins], By Cancer Type, By End User, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-23頁數 170報告編號 INSIGHTACE-83a227c77b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The CD Antigen Cancer Therapy Market on a global scale was estimated at USD 26.2 Bn in 2023 and is expected to attain USD 41.8 Bn by 2031, with a projected CAGR of 6.21% between 2024 and 2031.
At its core, CD Antigen Cancer Therapy pertains to a tailored treatment method that targets specific proteins on the surface of cancer cells. Stakeholders across the healthcare landscape are risingly turning to these solutions to meet contemporary demands.
Market momentum is underpinned by rising need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CD Antigen Cancer Therapy Market Snapshot
Chapter 4. Global CD Antigen Cancer Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
5.1. By Type of CD Antigen Targeted & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type of CD Antigen Targeted:
5.2.1. CD19
5.2.2. CD20
5.2.3. CD30
5.2.4. CD33
5.2.5. CD38
5.2.6. CD70
5.2.7. Others
Chapter 6. Market Segmentation 2: By Therapy Type Estimates & Trend Analysis
6.1. By Therapy Type & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapy Type:
6.2.1. Monoclonal Antibodies (mAbs)
6.2.2. Antibody-Drug Conjugates (ADCs)
6.2.3. Chimeric Antigen Receptor (CAR) T-cell Therapy
6.2.4. Bi-specific T-cell Engagers (BiTEs)
6.2.5. Radioimmunotherapy
6.2.6. Immunotoxins
Chapter 7. Market Segmentation 3: By Cancer Type Estimates & Trend Analysis
7.1. By Cancer Type & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Cancer Type:
7.2.1. Leukemia
7.2.2. Lymphoma
7.2.3. Multiple Myeloma
7.2.4. Breast Cancer
7.2.5. Lung Cancer
7.2.6. Prostate Cancer
7.2.7. Others
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End User:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Cancer Treatment Centers
8.2.4. Research Institutes
Chapter 9. CD Antigen Cancer Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.1.2. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.1.3. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.1.4. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.1.5. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.2. Europe
9.2.1. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.2.2. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.2.3. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.2.4. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.2.5. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.3. Asia Pacific
9.3.1. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.3.2. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.3.3. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.3.4. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.3.5. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.4. Latin America
9.4.1. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.4.2. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.4.3. Latin America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.4.4. Latin America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.4.5. Latin America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.5.2. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.5.3. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.5.4. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.5.5. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Novartis AG
10.2.2. Roche Holdings AG
10.2.3. Bristol Myers Squibb Company
10.2.4. Gilead Sciences Inc.
10.2.5. Merck & Co. Inc.
10.2.6. Johnson & Johnson
10.2.7. Amgen Inc.
10.2.8. AbbVie Inc.
10.2.9. AstraZeneca PLC
10.2.10. Takeda Pharmaceutical Company Limited
10.2.11. Seattle Genetics Inc.
10.2.12. Biogen Inc.
10.2.13. Celgene Corporation
10.2.14. Genmab A/S
10.2.15. Immunomedics Inc.
10.2.16. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們